Hot Investor Mandate: USA-Based VC Invests Up to $40M in Clinical Stage Therapeutics in Oncology, Rare Diseases, and More with Focus on US and Europe

21 Dec

A USA-based firm with multiple billion dollars of assets under management, invests from its latest fund that closed in 2023. The firm makes investments in the form of equity (preferred stock) and is an activist investor; the firm prefers to lead investments, take a board seat at its portfolio companies and be actively involved in company management. The firm plans to make 6-8 new investments in life science companies per year. 

The firm invests in biopharmaceuticals and typically makes initial investments of $5-15m, with the potential for a total investment of $15-40m.  The fund invests in companies based globally, with a focus on North America or Europe. 
 
The firm invests exclusively in therapeutics.  The firm will consider opportunities in any indication area but generally does not invest in cardiovascular disorders, diabetes, or other acute chronic care fields. The firm is particularly interested in oncology, specialty drugs, orphan drugs, and other areas where there is a defined clinical path to move the asset toward approval.  While the firm usually only invests in assets in Phase II or Phase III, the firm may consider earlier opportunities in oncology, ophthalmology, dermatology, and infectious diseases.  The firm is open to working with companies in any area of therapeutic technology but is particularly interested in biologics, and has also invested in biosimilars.   

In addition to investing in existing companies, this fund also invests in spinouts (typically from pharma companies); for spinouts, Phase II or earlier products are more likely to be considered as the pharma companies are typically able to provide a significant amount of trial data. 
 
The firm prefers to back management teams that have worked together before; it’s preferred that the team have experience of launching products, and have worked in both small and large biotech companies.  While experience is an important consideration, the firm has also worked with first-time CEOs.  For investments other than spinouts, the firm prefers to work with privately-held companies but also has past experience of PIPEs. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
 

Hot Investor Mandate: IVD Company Strategically Invests and Partners With Diagnostics and Digital Healthcare Companies Across the Globe

21 Dec

A global leading IVD (in vitro diagnostics) company has its main business in hematology, hematosis, urinalysis, immunochemistry, and clinical chemistry with over $3B in net sales. Regarding their Digital Healthcare Section, the office is in the Bay Area in Northern California and is scouting for opportunities in North America, from startups to co-development and co-investment, to compliment the firm’s internal product portfolio (e.g. blood biomarkers) and expand their digital healthcare business. Equity investments are made on a case-by-case basis, but when applicable, the corporation is looking for companies generally in Series A and B rounds with typical check size ranging from $1-10M USD. The corporation will also provide commercialization support in Japan and overseas markets. 
 
The firm is currently looking for companies that strategically align with their main business as well as (1) finding digital technologies that can assist with patient stratification and early risk identification to increase testing volume on the firm’s IVD tests (early identification), (2) digital therapeutics that can increase the value of diagnostics, and (3) enter new areas of homecare by utilizing blood biomarker assets and digital solutions. Subsectors include, but are not limited to, digital health, home care, digital therapeutics, digital biomarkers, and clinical decision support. Companies should typically be conducting clinical trials however, pre-clinical stages may be of considered. Interested indications are CNS diseases, cardiovascular diseases, lifestyle diseases (e.g. hypertension), mental health, and chronic kidney diseases. 
 
The firm does not have specific management team requirements. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Hot Investor Mandate: VC Firm Invests in USA-Based Digital Health and Tech Enabled Healthcare Services Companies in Venture and Growth Stage

21 Dec

A venture capital firm with USA offices is currently seeking new investments in the healthcare IT and tech enabled healthcare services sectors. The firm has raised 5 healthcare funds over the last 15 years and is currently deploying out of a late-seed stage focused as well as a Series A focused fund. The firm looks to invest in companies at venture and growth stage. The initial investment size typically ranges from $2 -$6 million. 
 
The firm is looking for new investments in the Healthcare IT and tech enabled healthcare services sectors. The firm focuses on healthcare companies targeting software, platform technology, solutions, data, and analytics. The fund is most interested in companies seeking to improve patient care and the provider experience, reduce healthcare costs, or make the healthcare industry more efficient in this rapidly changing marketplace. The firm has been active in HCIT companies developing eSource technology for use in clinical trials, clinical documentation intelligence, EHR system, and online source of research tools for global life science laboratories. 
 
The firm typically invests in private companies that have between $500K-$7M of annual revenue with a proven product and customer base. The firm typically looks to be a lead investor and usually requires a board or board observer seat post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Hot Investor Mandate: Single Family Office Invests in Seed to Series C Medical Device Companies, With Strong Interest in Surgical Solutions

21 Dec

A family office investment firm based in the US. The firm is actively seeking investment opportunities in the medtech space. Typical investment size is $250K, though the firm is capable of investing up to $1M. The firm invests anywhere from Seed to Series C rounds (growth/revenue-generating stage), and prefers to invest in USA-based companies. 
 
Within life sciences, the firm is primarily interested in medical devices. In particular, the firm is interested in surgical devices targeting areas including cancer, orthopedics, renal, cardiovascular, and neuro-related diseases as well as sepsis. The firm is open to companies in the earliest stages though they would like to see a working prototype in place prior to investment. The firm invests in all classes of medical devices including 510k and PMA. 
 
The firm has no specific company or management team requirements. The firm prefers to act as a co-investor. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Announcing Speaker Lineup at RESI JPM 2024

14 Dec

Joey Wong, Senior Investor Research Analyst, Hong Kong BD, LSN

RESI JPM 2024 is less than a month away. For this highly anticipated conference, LSN’s Investor Research Team has curated a lineup of 7 panels covering a wide range of topics relevant to early-stage investments and innovations.

Some of these panels will highlight specific leading or emerging sectors/ indications, such as Early-Stage Therapeutics, Medical Devices and Mental and Behavioral health, aiming to discuss cutting edge innovations, latest investment trends and the future outlook in these areas. Other panels will focus on different types of investors or strategics partners, such as Big Pharma, Health System Partners, Cross Border Investments and Family Offices, featuring active investors from corresponding groups to shed light on their investment approaches and strategies, recent deals or activities, the roles their play in the ecosystem, and how companies can seek to work with group like theirs, etc.

We are honored to be joined by a diverse group of panelists from around the globe, each bringing unique backgrounds and experiences. Through organizing these panels, our goal is to foster communications, bridge the gap between entrepreneurs and investors/strategic partners and assist founders and CEOs in navigating their fundraising and business development journey in this highly competitive landscape. If you are around for JPM, don’t miss the opportunity to hear from and connect with seasoned investors and executives at these RESI panels!

Here are the speakers for RESI JPM 2024:

Brent Ahrens
Brent Ahrens
General Partner
Canaan Partners
Jing Bao
Jing Bao
Partner
Shanghai Healthcare Capital
Tara Bishop
Tara Bishop
Founder & Managing Director
Black Opal Ventures
Scarlett Chen
Scarlett Chen
Managing Partner
Verge Health Tech Fund
William Dai
William Dai
Founding Partner
ShangBay Capital
Jakob Dupont
Jakob Dupont
Executive Partner, Private Equity
Sofinnova Investments
Alex Fair
Alex Fair
Managing Partner
Medstartr Ventures
Marissa Fayer
Marissa Fayer
U.S. Partner
Goddess Gaia Ventures
Les Funtleyder
Les Funtleyder
Healthcare Portfolio Manager
E Squared Capital
Viral Gandhi
Viral Gandhi
Principal
KCK MedTech
Lindsay Hoover
Lindsay Hoover
Managing Partner
JLS Fund
Jochen Hurlebaus
Jochen Hurlebaus
Head of Digital Health Innovation
Roche Diagnostics
Marc Jones
Marc Jones
CEO
Altoida Inc
Ekaterine Kortkhonjia
Ekaterine Kortkhonjia
Sr. Director, Early Innovation Partnering
Johnson & Johnson Innovation
Michael Langer
Michael Langer
Founder & Managing Partner
T.Rx Capital
Linda Li
Linda Li
Partner, Digital Health
Cleveland Clinic Ventures
James Mayer
James Mayer
Partner, CABHI Ventures
Centre for Aging + Brain Health Innovation (CABHI)
Jeffrey Moore
Jeffrey Moore
President
MP Healthcare Venture Management (MPH)
Miguel Moreno Garcia
Miguel Moreno Garcia
Director of Research
SENS Research Foundation
Ahmed Mousa
Ahmed Mousa
Business Development Executive
Tamer Group
Priya Oberoi
Priya Oberoi
Managing General Partner
Goddess Gaia Ventures
John Pennett
John Pennett
Angel Investor
Mid Atlantic Bio Angels
Rachel Rea
Rachel Rea
Senior Director, Business Development
Stryker
Liridon Rrushaj
Liridon Rrushaj
Director, Venture Investments
OSF Ventures
Dennis Sacha
Dennis Sacha
Principal
IAG Capital Partners
Diana Saraceni
Diana Saraceni
Founder, Managing Director
Panakes Partners
Matias Serebrinsky
Matias Serebrinsky
Co-Founder & General Partner
PsyMed Ventures
 Ashim Subedee
Ashim Subedee
Director, Catalyst Office
Division of Research Innovation and Ventures (DRIVe)
Prasad Sunkara
Prasad Sunkara
Board of Directors
NuFund Venture Group
LAUREN TYRA, PH.D.
Lauren Tyra
Chief Scientific Officer
Green Park & Golf Ventures
Akili Wallace
Akili Wallace
Director and Deal Lead in Business Development Transactions
Amgen
Tyler Wanke
Tyler Wanke
Investor
Wanke Family Office
Anita Watkins
Anita Watkins
Managing Director
Rex Health Ventures
Dana Watt
Dana Watt
Principal
Breakout Ventures
Tad Weems
Tad Weems
Managing Director
Agilent Technologies
Andrew Wong
Andrew Wong
Global Head of Bayer CoLabs
Bayer
Shann Yu
Shann Yu
Associate Director
AbbVie Ventures

RESI-SF-2024-Banner-1100px new

Maximizing Success in Partnering Conferences: Strategic Metrics and Conference Navigation 

14 Dec

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series

Partnering conferences offer a dynamic environment where innovators, capital investors, and licensing partners converge to explore collaboration opportunities. Amidst the vibrant panels and workshops, one-on-one meetings, and pitch sessions, it’s essential for participants to approach each interaction strategically. RESI is distinctly unique because there is a 50/50 ratio of buy-side partners and sell-side startups at our events. This is the main differentiator for a RESI versus other partnering events, which will typically be 10-15% buy-side partners to sell-side startups. This is driven by LSN’s investor database, that five full-time staff have been curating for over a decade. The LSN team regularly interacts with the 4000 early-stage investors and licensing partners that are in our network, allowing LSN to leverage these relationships and recruit buy-side partners to judge slots for our pitch competitions and use LSN events to source technology assets for their portfolio requirements.

Partnering Conference Dynamics

Assessing the success of a partnering event can be done with multiple metrics, as there are multiple avenues to achieve your goals. Is the investor interested in a follow-up meeting, and potentially initiating due diligence? Will the investor introduce you to other investors who could be a potential fit for you? Can the investor provide you with valuable advice, even if they don’t invest themselves? Are they a potential fit for future rounds, and initiating the relationship now can help move that forward when you are ready? All of these can be considered a success, even if it doesn’t end with cash in your hand from this specific investor or licensing partner.

Importance of Meeting Metrics

Fit as the Core Metric: Prioritize meetings based on alignment with the company’s stage and product. Quality trumps quantity for meaningful collaboration.

Follow-up Meetings: Success is measured by investor interest in follow-up meetings, indicating engagement and potential for ongoing dialogue.

Interest in NDAs: For intellectual property discussions, investors’ willingness to sign NDAs reflects commitment to exploration and idea value acknowledgment.

Referrals and Network Expansion: Referrals broaden the network, signaling positive reception within the industry.

Engagement Beyond Meetings: Meaningful connections extend beyond formal settings. Investor engagement in networking activities signals potential rapport beyond scheduled interactions.

Technology for Meeting Success: The RESI Conference Series utilizes a sophisticated “matching algorithm,” ensuring strategic connections based on compatibility, not random encounters.

Strategic Thinking for Success

Navigating partnering conference meetings requires strategic thinking. Executives must assess meetings aligning with goals and potential collaboration. Metrics such as fit, interest in follow-ups, NDAs, referrals, and engagement gauge success. Partnering conferences offer a fertile ground for critical partnerships, with success dependent on thoughtful consideration of meeting metrics, contributing to strategic growth in the complex landscape of early-stage financing.
RESI-SF-2024-Banner-1100px new

RESI JPM – A Global Gathering 

14 Dec

By Greg Mannix, Vice President International Business Development, General Manager Europe, LSN

RESI JPM, during JP Morgan week takes place in the major life science hub that is San Francisco and will, of course, have a great concentration of the hottest technologies being developed in the Bay Area and the plethora of VCs, Angels, Family Offices and Pharma/Medtech giants that help to fuel this amazing ecosystem.  But RESI, wherever it happens to take place, is always a truly international gathering, and the upcoming edition is no exception. RESI JPM will take place Tuesday, January 9, in person at the historic Marine’s Memorial Club and Hotel, followed by two days of virtual partnering, January 11-12.

As of today, attendees at RESI JPM will be representing 31 countries spanning 5 continents and will be looking to meet with investors and licensing partners from Asia, Europe, and North America. 35% of the investors and Big Pharma/Medtech attendees are from outside the US.

We are also looking forward to welcoming Tech Hubs, Regional Organizations, and Accelerators—the groups that advocate for and support the life sciences industries in their regions—coming from Australia, Canada, Chile, The Netherlands, Singapore, Spain, and the United States.

  • The Brisbane Economic Development Agency and the Government of Queensland (Australia) will be supporting a cohort of great companies from Down Under who will be presenting in the Innovator’s Pitch Challenge.
  • From Spain, the Catalonian biotechnology organization Biocat will be present to drum up interest in our first conference to take place in Spain:  RESI Europe will be in Barcelona from June 17-19, 2024.
  • From Canada, regional tech hubs from 3 provinces will be present—British Columbia, Ontario and Quebec.
  • We are also looking forward to seeing The Ganesha Lab accelerator from Chile, supporting innovative technologies from all over Latin America.
  • From Japan, Life Science Incubation Council, a newly formed consortium to support the life sciences sector in Japan for global partnership and collaboration will be in attendance.
  • From Singapore, Enterprise Singapore, a government agency dedicated to supporting the growth of Singapore-based companies will be at RESI.

At LSN we believe in bringing people together from around the globe to tear down barriers to achieve a common goal of supporting the life sciences. Welcome to all our international attendees this January!

Greg-1

Greg-2

RESI-SF-2024-Banner-1100px new